New treatments for respiratory syncytial virus (RSV)
Polymerase Inhibitors of Respiratory Syncytial Virus
This study is looking for new oral medications to help treat respiratory syncytial virus (RSV), which can be really tough for babies, older adults, and those with weakened immune systems, so we can find safer and more effective options for those at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10873994 on NIH RePORTER |
What this research studies
This research focuses on developing new antiviral medications specifically targeting respiratory syncytial virus (RSV), which is a leading cause of hospitalization in infants and can be severe for the elderly and immunocompromised individuals. The project aims to evaluate two classes of polymerase inhibitors that have shown promise in preliminary studies, using advanced techniques to assess their effectiveness and safety. By conducting rigorous preclinical testing, the researchers hope to identify effective oral treatments that could be widely applicable for patients at risk of RSV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research include infants, young children, elderly individuals, and immunocompromised patients who are at higher risk for severe RSV infections.
Not a fit: Patients who are not at risk for RSV infection or those who do not meet the age and health criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective oral antiviral treatments for RSV, potentially reducing hospitalizations and improving outcomes for affected patients.
How similar studies have performed: Previous research has shown promise in developing antiviral treatments for RSV, but this specific approach using polymerase inhibitors is relatively novel.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Plemper, Richard K. — Georgia State University
- Study coordinator: Plemper, Richard K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.